Hypertension
Conditions
Interventions
Interventional group:In addition to standard antihypertensive therapy (SoC), one tablet of SGLT2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg) was administered daily. Other antihypertensive m
any adjustments according to guidelines required detailed documentation.
Control group:Continue current standard antihypertensive therapy (SoC) without the use of SGLT2 inhibitors.
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
All
Age
30 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Aged 30 to 80, diagnosed with essential hypertension. 2. Left ventricular ejection fraction (LVEF) >=50%. 3.Evidence of abnormal LA function/load (meeting any of the following conditions) : (1) LASr 0.6 (3) LAVI > 34 mL/m^2. 4.Currently receiving standard antihypertensive treatment with a stable regimen for at least 4 weeks. 5.Voluntarily sign the informed consent form and be able to cooperate in completing all research visits and examinations.
Exclusion criteria
Exclusion criteria: 1. The estimated glomerular filtration rate (eGFR) is less than 45 mL/min/1.73 m^2 or there are contraindications for the use of SGLT2i. 2. There is a history of recurrent urinary and reproductive system infections or diabetic ketoacidosis. 3. Accompanied by significant valvular heart disease, recent acute coronary syndrome, myocarditis or a history of cardiac surgery. 4. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left atrial reservoir strain; | — |
Secondary
| Measure | Time frame |
|---|---|
| Left atrial functional reserve;Left Atrial Volume Index;Left Atrial Stiffness Index;Left Ventricular Global Longitudinal Strain;Diastolic Function Parameters ;Tricuspid Regurgitation Velocity; | — |
Countries
China
Contacts
Public ContactFu Huaying
The Second Hospital of Tianjin Medical University
Outcome results
None listed